SS

Satwant Singh

Active Director Director DIN 06420859
DIN 06420859 First appointment Nov 2012 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 5 active board seats
Past companies 1 historical roles
Total affiliations 6 Since Nov 2012
Shareholding value •••• Premium profile

About Satwant Singh

Data last updated:

Satwant Singh is a Director at Grapple Lifesciences Private Limited (since 2012), Director at Ampira Biotechnics Private Limited (since 2019) and Director at Medlex Biotechnics Private Limited (since 2020), and holds 2 more current directorships. The companies operate in Pharma and Healthcare. The 4 current companies with reported revenue have a combined latest revenue of ₹19.44 Cr; the largest is Grapple Lifesciences Private Limited at ₹8.93 Cr (FY 2025). Earlier, Satwant Singh was a Director at Clabert Lifesciences Private Limited (2018–2023).

DIN 06420859
Primary Designation Director
Industry Pharma
First Appointment 20 Nov 2012
Oldest Company Age 15 yrs
Largest company Grapple Lifesciences Private Limited · ₹8.93 Cr (FY 2025)
Combined revenue ₹19.44 Cr across 4 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Grapple Lifesciences Private Limited U24230CH2011PTC033379
Director20 Nov 20122011₹8.93 Cr (FY 2025)Active
Ampira Biotechnics Private Limited U24239CH2019PTC042374
Director12 Feb 20192019₹7.07 Cr (FY 2024)Active
Medlex Biotechnics Private Limited U24290CH2020PTC043399
Director16 Dec 20202020₹3.20 Cr (FY 2024)Active
Livin Herbal Private Limited U24299CH2020PTC043361
Director28 Aug 20242020₹23.6 Lakh (FY 2024)Active
Qantas Labs Private Limited U24239CH2020PTC043400
Director16 Dec 20202020Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Clabert Lifesciences Private Limited U74999CH2018PTC041859
Director12 Feb 20182018₹1.23 Cr (FY 2024)Active

Explore Director's current and past company associations Uncover their professional journey today!

Board colleagues of Satwant Singh

Directorship timeline

Open interactive timeline →
Livin Herbal Private Limited
Grapple Lifesciences Private Limited
Ampira Biotechnics Private Limited
Qantas Labs Private Limited
Premium access

Shareholding and investment profile for Satwant Singh

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Satwant Singh

Satwant Singh currently holds 5 directorships: Grapple Lifesciences Private Limited (Director, since 20 Nov 2012, revenue ₹8.93 Cr (FY 2025)); Ampira Biotechnics Private Limited (Director, since 12 Feb 2019, revenue ₹7.07 Cr (FY 2024)); Medlex Biotechnics Private Limited (Director, since 16 Dec 2020, revenue ₹3.20 Cr (FY 2024)); Livin Herbal Private Limited (Director, since 28 Aug 2024, revenue ₹23.6 Lakh (FY 2024)); Qantas Labs Private Limited (Director, since 16 Dec 2020).

Satwant Singh was first appointed on 20 Nov 2012 as Director at Grapple Lifesciences Private Limited. The most recent appointment on record is 28 Aug 2024 at Livin Herbal Private Limited.

The 4 current companies of Satwant Singh that report revenue have a combined latest revenue of ₹19.44 Cr: Grapple Lifesciences Private Limited ₹8.93 Cr (FY 2025); Ampira Biotechnics Private Limited ₹7.07 Cr (FY 2024); Medlex Biotechnics Private Limited ₹3.20 Cr (FY 2024); Livin Herbal Private Limited ₹23.6 Lakh (FY 2024).

Satwant Singh held 1 earlier board appointment: Clabert Lifesciences Private Limited (Director, 12 Feb 2018 to 29 Dec 2023).

The current boards of Satwant Singh's companies include Ajay (Grapple Lifesciences Private Limited), Babita (Ampira Biotechnics Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available